Poolbeg Pharma
plc
Director Share
Purchase
19 February 2024 - Poolbeg
Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'),
a biopharmaceutical company focussed on the
development and commercialisation of innovative medicines targeting
diseases with a high unmet medical need,
announces that it has received notification that on 19 February
2024, Cathal Friel, Executive Chairman of the Company, purchased
830,000 ordinary shares at a price of 11.68 pence per share (the
"Purchase").
Following the Purchase, Cathal holds
37,219,757 ordinary shares representing approximately 7.4 per cent
of the Company's issued share capital.
The information contained within
this announcement is deemed by the Company to constitute inside
information as stipulated under the Market Abuse Regulations (EU)
No. 596/2014 (as implemented into English law) ("MAR"). With the
publication of this announcement via a Regulatory Information
Service, this inside information is now considered to be in the
public domain.
Enquiries
|
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO
|
+44 (0) 207 183 1499
|
|
Cavendish Capital Markets
Ltd (Nominated Adviser & Joint Broker)
Geoff Nash, Charlie
Beeson, Nigel Birks, Harriet Ward (ECM)
|
+44 (0) 207 220 0500
|
|
Singer Capital Markets (Joint
Broker)
Phil Davies, Sam
Butcher
|
+44 (0) 207 496
3000
|
|
J&E Davy (Joint
Broker)
Anthony Farrell, Niall
Gilchrist
|
+353 (0) 1 679 6363
|
|
Optimum Strategic
Communications
Nick Bastin, Vici Rabbetts,
Elena Bates
|
+44 (0) 208 078 4357
poolbeg@optimumcomms.com
|
About Poolbeg Pharma
Poolbeg Pharma plc is committed to
the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need. Its model
focusses upon developing its exciting clinical assets and
commercialising approved and marketed drugs to fund the development
of its robust pipeline of innovative products, thereby driving
significant value creation.
Poolbeg is led by an experienced
leadership team with a history of delivering significant
shareholder value. The team has been strengthened by the
appointment of three former members of the Amryt Pharma plc
leadership team, with the intention of repeating Amryt's success
and generating near term revenues.
Poolbeg's clinical programmes target
large addressable markets including cancer immunotherapy-induced
CRS, infectious disease, and metabolic conditions such as obesity
with the development of an oral GLP-1R agonist. It uses a
cost-effective development philosophy to generate high quality
human data to support partnering and further development. Its
AI-led infectious disease programmes analyse unique data from human
challenge trials to identify clinically relevant drug targets and
treatments, leading to faster development and greater commercial
appeal.
For more information, please go
to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
Forward-Looking
Statements
This announcement may contain forward-looking statements and the words "expect",
"anticipate", "intends", "plan", "estimate", "aim", "forecast",
"project" and similar expressions (or their negative) identify
certain of these forward-looking statements. The forward-looking
statements in this announcement are based on numerous assumptions
and Poolbeg's present and future business strategies and the
environment in which Poolbeg expects to operate in the future.
Forward-looking statements involve inherent known and unknown
risks, uncertainties and contingencies because they relate to
events and depend on circumstances that may or may not occur in the
future and may cause the actual results, performance or
achievements to be materially different from those expressed or
implied by such forward-looking statements. These statements are
not guarantees of future performance or the ability to identify and
consummate investments. Many of these risks and uncertainties
relate to factors that are beyond Poolbeg's ability to control or
estimate precisely, such as future market conditions, currency
fluctuations, the behaviour of other market participants, the
outcome of clinical trials, the actions of regulators and other
factors such as Poolbeg's ability to obtain financing, changes in
the political, social and regulatory framework in which Poolbeg
operates or in economic, technological or consumer trends or
conditions. Past performance should not be taken as an indication
or guarantee of future results, and no representation or warranty,
express or implied, is made regarding future performance. No person
is under any obligation to update or keep current the information
contained in this announcement or to provide the recipient of it
with access to any additional relevant
information.
Notification and public
disclosure of transactions by persons discharging managerial
responsibilities and persons closely associated with
them:
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a.
|
Name of PDMR
|
Cathal Friel
|
|
2
|
Reason for notification
|
|
a.
|
Position/Status
|
Executive Chairman
|
|
b.
|
Initial notification/
Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
Poolbeg Pharma plc
|
|
b.
|
LEI
|
213800UZ8WJLWYHBFL52
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Ordinary shares of £0.002
each
ISIN GB00BKPG7Z60
|
|
b.
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c.
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
11.68p
|
830,000
|
|
d.
|
Aggregated information
- Aggregated Volume
- Price
|
As in 4c) above
|
|
e.
|
Date of the transaction
|
19 February 2024
|
|
f.
|
Place of the transaction
|
London Stock Exchange, AIM Market
(XLON)
|